RU2002129569A - NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS - Google Patents
NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS Download PDFInfo
- Publication number
- RU2002129569A RU2002129569A RU2002129569/15A RU2002129569A RU2002129569A RU 2002129569 A RU2002129569 A RU 2002129569A RU 2002129569/15 A RU2002129569/15 A RU 2002129569/15A RU 2002129569 A RU2002129569 A RU 2002129569A RU 2002129569 A RU2002129569 A RU 2002129569A
- Authority
- RU
- Russia
- Prior art keywords
- hypertension
- renal failure
- pharmaceutically acceptable
- combination
- restenosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19674200P | 2000-04-12 | 2000-04-12 | |
US60/196,742 | 2000-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002129569A true RU2002129569A (en) | 2004-03-27 |
Family
ID=22726655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002129569/15A RU2002129569A (en) | 2000-04-12 | 2001-04-10 | NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1282410A2 (en) |
JP (1) | JP2003530343A (en) |
KR (1) | KR20020089437A (en) |
CN (1) | CN1422152A (en) |
AR (1) | AR032316A1 (en) |
AU (2) | AU7393801A (en) |
BR (1) | BR0110079A (en) |
CA (1) | CA2405895A1 (en) |
HU (1) | HUP0301335A3 (en) |
IL (1) | IL152081A0 (en) |
MX (1) | MXPA02010091A (en) |
NO (1) | NO20024920L (en) |
NZ (1) | NZ521855A (en) |
PE (1) | PE20020082A1 (en) |
PL (1) | PL358459A1 (en) |
RU (1) | RU2002129569A (en) |
SK (1) | SK14612002A3 (en) |
WO (1) | WO2001076574A2 (en) |
ZA (1) | ZA200208204B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1368009A2 (en) * | 2000-07-27 | 2003-12-10 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
US6777443B2 (en) | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
ATE551056T1 (en) | 2002-12-27 | 2012-04-15 | Takeda Pharmaceutical | AGENT FOR INHIBITING BODY WEIGHT GAIN |
SE0300988D0 (en) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
ITTO20040760A1 (en) * | 2004-11-03 | 2005-02-03 | Uni Degli Studi Del Piemonte | USE OF A CORTICOSTEROID IN ASSOCIATION WITH OTHER ACTIVE PRINCIPLES FOR THE TREATMENT OF VASCULAR STENOSIS AND THE PREVENTION OF VASCULAR RESTENOSIS |
EP1674080A1 (en) * | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
PT2033629E (en) * | 2004-12-24 | 2013-01-24 | Krka | Solid pharmaceutical composition comprising valsartan |
WO2006092430A1 (en) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selective inhibitors of human corticosteroid synthases |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
GT200600381A (en) | 2005-08-25 | 2007-03-28 | ORGANIC COMPOUNDS | |
EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP2095819A1 (en) | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
BRPI1011657A2 (en) | 2009-05-28 | 2019-04-16 | Novartis Ag | substituted aminopropionic derivatives as neprilysin inhibitors |
SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US9867811B2 (en) | 2011-07-08 | 2018-01-16 | Novartis Ag | Method of treating atherosclerosis in high triglyceride subjects |
UY35144A (en) | 2012-11-20 | 2014-06-30 | Novartis Ag | APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT |
CN105073762B (en) | 2013-02-14 | 2017-03-08 | 诺华股份有限公司 | Substituted biphenyl butyryl phosphonate derivative as NEP (neutral endopeptidase) inhibitor |
MX2016001020A (en) | 2013-07-25 | 2016-08-03 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure. |
KR20160031552A (en) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | Bioconjugates of synthetic apelin polypeptides |
MA41580A (en) | 2015-01-23 | 2017-11-29 | Novartis Ag | SYNTHETIC APELIN FATTY ACID CONJUGATES WITH IMPROVED HALF-LIFE |
JOP20190086A1 (en) | 2016-10-21 | 2019-04-18 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
JP7130636B2 (en) | 2016-10-27 | 2022-09-05 | ダミアン ファーマ アーゲー | Aldosterone synthase inhibitor |
UY38072A (en) | 2018-02-07 | 2019-10-01 | Novartis Ag | COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME |
WO2020110008A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
CN113166204A (en) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders |
UY38485A (en) | 2018-11-27 | 2020-06-30 | Novartis Ag | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION |
WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
AR127698A1 (en) | 2021-11-23 | 2024-02-21 | Novartis Ag | NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252565A (en) * | 1990-04-02 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Haloethyl-substituted steroid enzyme inhibitors |
JPH0971586A (en) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | New bicyclic condensed imidazole derivative |
ES2229376T5 (en) * | 1996-07-22 | 2010-10-25 | Renovo Limited | USE OF COMPOUNDS THAT PROMOTE ESTROGENIC ACTIVITY TO ACCELERATE THE CICATRIZATION OF SKIN WOUNDS. |
US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
FR2766821A1 (en) * | 1997-07-29 | 1999-02-05 | Sanofi Sa | 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES |
US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
CA2336822C (en) * | 1998-07-10 | 2009-11-17 | Novartis Ag | Method of treatment and pharmaceutical composition |
-
2001
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/en not_active Application Discontinuation
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/en not_active Application Discontinuation
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/en unknown
- 2001-04-10 CA CA002405895A patent/CA2405895A1/en not_active Abandoned
- 2001-04-10 IL IL15208101A patent/IL152081A0/en unknown
- 2001-04-10 CN CN01807917A patent/CN1422152A/en active Pending
- 2001-04-10 EP EP01940317A patent/EP1282410A2/en not_active Withdrawn
- 2001-04-10 AR ARP010101698A patent/AR032316A1/en not_active Application Discontinuation
- 2001-04-10 AU AU7393801A patent/AU7393801A/en active Pending
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/en not_active Application Discontinuation
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/en not_active Application Discontinuation
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/en active Pending
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/en not_active IP Right Cessation
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/en not_active Application Discontinuation
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/en unknown
- 2001-04-10 PL PL01358459A patent/PL358459A1/en not_active Application Discontinuation
-
2002
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown
- 2002-10-11 NO NO20024920A patent/NO20024920L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0301335A2 (en) | 2003-08-28 |
HUP0301335A3 (en) | 2006-02-28 |
NO20024920D0 (en) | 2002-10-11 |
EP1282410A2 (en) | 2003-02-12 |
WO2001076574A3 (en) | 2002-04-25 |
AU7393801A (en) | 2001-10-23 |
ZA200208204B (en) | 2003-10-14 |
WO2001076574A2 (en) | 2001-10-18 |
NO20024920L (en) | 2002-11-27 |
AR032316A1 (en) | 2003-11-05 |
KR20020089437A (en) | 2002-11-29 |
CN1422152A (en) | 2003-06-04 |
JP2003530343A (en) | 2003-10-14 |
IL152081A0 (en) | 2003-05-29 |
PE20020082A1 (en) | 2002-02-21 |
BR0110079A (en) | 2002-12-31 |
AU2001273938B2 (en) | 2005-03-03 |
SK14612002A3 (en) | 2003-05-02 |
MXPA02010091A (en) | 2003-02-12 |
PL358459A1 (en) | 2004-08-09 |
NZ521855A (en) | 2004-10-29 |
CA2405895A1 (en) | 2001-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002129569A (en) | NEW MEDICAL APPLICATION OF ALDOSTEROSYNTHASE INHIBITORS INDIVIDUALLY OR IN COMBINATION WITH AT1-RECEPTOR ANTAGONISTS | |
JP2005533023A5 (en) | ||
US9592231B2 (en) | Therapy for complications of diabetes | |
AU753486B2 (en) | Method of treatment and pharmaceutical composition | |
US6204281B1 (en) | Method of treatment and pharmaceutical composition | |
TW200406204A (en) | Combination of organic compounds | |
JP2010507602A5 (en) | ||
RU2002129558A (en) | A COMBINATION AT LEAST OF TWO COMPOUNDS SELECTED FROM AT AN ANTAGONISTIC GROUPS, ACE RECEPTOR OR ACE INHIBITORS (ANGIOTENZIN-CONVERSING ENZYME) OR HMG-β-RESOURSE-RESIDUAL RESIDUES | |
EP1799199B1 (en) | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure | |
JP2018502883A5 (en) | ||
EP1487424B1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases | |
RU2008135692A (en) | ORGANIC X-COMPOUND COMBINATION | |
RU2020113612A (en) | TREATMENT OF FOCAL-SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS | |
RU2011105059A (en) | Application of pyrimidylamino-benzamide derivatives for the treatment of fibrosis | |
WO2017006254A1 (en) | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist | |
ZA200300972B (en) | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists. | |
JPWO2006028007A1 (en) | Treatment for glomerular diseases | |
IL276474B2 (en) | Substituted bisphenyl butanoic ester derivatives as nep inhibitors | |
RU2006119329A (en) | COMBINATIONS OF AT1-ANTAGONISTS, AMILORID OR TRIAMETERINE, AND DIURETICS | |
JP2005126338A (en) | Cardiac failure therapeutic agent | |
CA2677822A1 (en) | Antihypertensive drug combination | |
JP2010031006A (en) | Use of organic compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070313 |